About: Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in China

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in China Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in China
Creator	Wang, Yan Zhang, Wei Zhang, Jinxia Huang, Kai Ge, Junbo Xiang, Xin Yu, Bo Fang, Weiyi Gu, Xiaolong Huo, Yong Su, Xi Xiang, Dingcheng Xu, Yawei Yi, Shaodong
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: ST-segment elevation myocardial infarction (STEMI) is a fatal cardiovascular emergency requiring rapid reperfusion treatment. During the coronavirus disease-2019 (COVID-19) pandemic, medical professionals need to strike a balance between providing timely treatment for STEMI patients and implementing infection control procedures to prevent nosocomial spread of COVID-19 among health care workers and other vulnerable cardiovascular patients. OBJECTIVES: This study evaluates the impact of the COVID-19 outbreak and China Chest Pain Center’s modified STEMI protocol on the treatment and prognosis of STEMI patients in China. METHODS: Based on the data of 28,189 STEMI patients admitted to 1,372 Chest Pain Centers in China between December 27, 2019 and February 20, 2020, the study analyzed how the COVID-19 outbreak and China Chest Pain Center’s modified STEMI protocol influenced the number of admitted STEMI cases, reperfusion strategy, key treatment time points, and in-hospital mortality and heart failure for STEMI patients. RESULTS: The COVID-19 outbreak reduced the number of STEMI cases reported to China Chest Pain Centers. Consistent with China Chest Pain Center’s modified STEMI protocol, the percentage of patients undergoing primary percutaneous coronary intervention declined while the percentage of patients undergoing thrombolysis increased. With an average delay of approximately 20 min for reperfusion therapy, the rate of in-hospital mortality and in-hospital heart failure increased during the outbreak, but the rate of in-hospital hemorrhage remained stable. CONCLUSIONS: There were reductions in STEMI patients’ access to care, delays in treatment timelines, changes in reperfusion strategies, and an increase of in-hospital mortality and heart failure during the COVID-19 pandemic in China.
has issue date	2020-08-19(xsd:dateTime)
bibo:doi	10.1016/j.jacc.2020.06.039
bibo:pmid	32828614
has license	no-cc
sha1sum (hex)	10552125b8bfb2261ea55c54cca6c235b5b3e553
schema:url	https://doi.org/10.1016/j.jacc.2020.06.039
resource representing a document's title	Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in China
has PubMed Central identifier	PMC7438071
has PubMed identifier	32828614
schema:publication	J Am Coll Cardiol
resource representing a document's body	covid:10552125b8bfb2261ea55c54cca6c235b5b3e553#body_text
is schema:about of	named entity 'China' named entity 'protocol' named entity 'patients' named entity 'infection control' named entity 'ST-segment elevation myocardial infarction' named entity 'nosocomial' named entity 'patients' named entity 'STEMI' named entity 'patients' named entity 'cardiovascular' named entity 'health care workers' named entity 'Pandemic' named entity 'cardiovascular' named entity 'ST-segment elevation myocardial infarction' named entity 'STEMI' named entity 'COVID' named entity 'COVID-19 outbreak' named entity 'Chest Pain Center' named entity 'STEMI' named entity 'During' named entity 'STEMI' named entity 'primary PCI' named entity 'Hong Kong' named entity 'statistically significant' named entity 'China' named entity 'COVID-19' named entity 'public transportation' named entity 'Australia' named entity 'prognosis' named entity 'nosocomial' named entity 'Regression analysis' named entity 'medical professionals' named entity 'COVID-19' named entity 'statistically significant' named entity 'COVID-19 outbreak' named entity 'cardiac catheterization' named entity 'COVID-19' named entity 'prognosis' named entity 'observational studies' named entity 'STEMI' named entity 'STEMI' named entity 'United States' named entity 'small sample' named entity 'COVID-19' named entity 'significant effect' named entity 'COVID-19' named entity 'Palestine' named entity 'empirical study' named entity 'primary PCI' named entity 'COVID-19 pandemic' named entity 'STEMI' named entity 'Hubei' named entity 'STEMI' named entity 'prognosis' named entity 'Iran' named entity 'primary PCI' named entity 'COVID-19' named entity 'United States' named entity 'Italy' named entity 'primary PCI' named entity 'Spain' named entity 'nosocomial infection' named entity 'COVID-19 outbreak' named entity 'personal protective equipment' named entity 'New Zealand' named entity 'personal protective equipment' named entity 'thrombolytic' named entity 'interaction term'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software